OncoMatch/Clinical Trials/NCT03690986
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Is NCT03690986 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including VX15/2503 and Ipilimumab for squamous cell carcinoma of the head and neck.
Treatment: VX15/2503 · Ipilimumab · Nivolumab — This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Allowed: CDKN2A p16 positive and negative allowed
p16 positive and negative allowed
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: any treatment for hnscc
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500 cells/µL; Platelets ≥ 100,000/µL; Hemoglobin ≥ 9.0g/dL (may receive prbc transfusion)
Kidney function
Serum creatinine ≤ 1.5 x ULN; Calculated creatinine clearance of ≤ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN; Albumin ≥ 3.0 g/dL
Absolute neutrophil count ≥ 1,500 cells/µL; Platelets ≥ 100,000/µL; Hemoglobin ≥ 9.0g/dL (may receive packed red blood cell [prbc] transfusion); Total bilirubin ≤ 1.5 x ULN; AST and ALT ≤ 2.5 x ULN; Albumin ≥ 3.0 g/dL; Serum creatinine ≤ 1.5 x ULN; Calculated creatinine clearance of ≤ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital Midtown · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify